Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Suzanne Kyle.

Newcastle AuthorsTitleYearFull text
Dr Catherine Willoughby
Huw Thomas
Dr Elaine Willmore
Suzanne Kyle
Dr Anita Wittner
et al.
Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy2019
Carlo Bawn
Dr Martin Galler
Huw Thomas
Suzanne Kyle
Professor Nicola Curtin
et al.
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS2017
James Murray
Huw Thomas
Philip Berry
Suzanne Kyle
Dr Miranda Patterson
et al.
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules2014
Michael Batey
Dr Yan Zhao
Suzanne Kyle
Professor Herbie Newell
Professor Nicola Curtin
et al.
Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer2013
Dr Emma Haagensen
Suzanne Kyle
Dr Gary Beale
Dr Ross Maxwell
Professor Herbie Newell
et al.
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition2012
Huw Thomas
Suzanne Kyle
Ivanda Pavlovska
Professor Nicola Curtin
The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice2011
Dr Yvette Drew
Dr Evan Mulligan
Wan Vong
Huw Thomas
Suzanne Kyle
et al.
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA22011
Huw Thomas
Suzanne Kyle
Rafal Zur
Dr Evan Mulligan
Professor Nicola Curtin
et al.
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance2010
Dr Asima Mukhopadhyay
Dr Ahmed Elattar
Dr Aiste McCormick
Sarah Wilkinson
Dr Yvette Drew
et al.
Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors2010
Huw Thomas
Suzanne Kyle
Tim Robson
Professor Nicola Curtin
Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?2009
Suzanne Kyle
Huw Thomas
Dr Jane Mitchell
Professor Nicola Curtin
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer2008
Dr Yvette Drew
Suzanne Kyle
Professor Richard Edmondson
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic cancers? [abstract]2008
Huw Thomas
Dr Christopher Calabrese
Michael Batey
Suzanne Kyle
Professor Herbie Newell
et al.
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial2007
Huw Thomas
Kathleen Parker
Suzanne Kyle
Professor Nicola Curtin
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase2005
Dr Christopher Calabrese
Michael Batey
Professor Alan Calvert
Professor barbara Durkacz
Suzanne Kyle
et al.
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG143612004
Dr Christopher Calabrese
Professor Nicola Curtin
Suzanne Kyle
Huw Thomas
Lan Wang
et al.
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase2004
Professor Nicola Curtin
Lan Wang
Suzanne Kyle
Dr Christine Arris
Professor barbara Durkacz
et al.
Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells2004
Professor Nicola Curtin
Emeritus Professor Bernard Golding
Suzanne Kyle
Professor Roger Griffin
Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors2004
Dr Christopher Calabrese
Michael Batey
Huw Thomas
Professor barbara Durkacz
Lan Wang
et al.
Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies2003
Dr Christopher Calabrese
Professor Nicola Curtin
Suzanne Kyle
Huw Thomas
Lan Wang
et al.
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure2002
Professor Nicola Curtin
Dr Stephen Barton
Michael Batey
Dr Christopher Calabrese
Professor Alan Calvert
et al.
Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.2001
Professor Nicola Curtin
Professor Alan Calvert
Professor barbara Durkacz
Professor Roger Griffin
Emeritus Professor Bernard Golding
et al.
Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines.2000
Dr Christopher Calabrese
Professor Nicola Curtin
Michael Batey
Huw Thomas
Suzanne Kyle
et al.
Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase2000
Suzanne Kyle
Professor barbara Durkacz
Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin2000
Lan Wang
Suzanne Kyle
Alex White
Professor Alan Calvert
Professor Nicola Curtin
et al.
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines2000
Suzanne Kyle
Professor barbara Durkacz
Cytotoxic mechanism of the protein kinase inhibitor wortmannin in ionising radiation and etoposide treated cells1999
Suzanne Kyle
Professor barbara Durkacz
Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage1999
Professor Nicola Curtin
Suzanne Kyle
Lan Wang
Professor barbara Durkacz
Professor Roger Griffin
et al.
Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors1999
Suzanne Kyle
Professor barbara Durkacz
Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: Effects on NAD metabolism and DNA repair1997
Suzanne Kyle
Professor barbara Durkacz
Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells1996